Gane, Edward J <br/><br/>
Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen.  [electronic resource] 

 -  Hepatology (Baltimore, Md.)  10 2017 
 - 1083-1089 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-3350 
<br/><br/><label>Standard No.: </label>10.1002/hep.29256  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antiviral Agents--therapeutic use<br/>Carbamates--therapeutic use<br/>Drug Combinations<br/>Drug Resistance, Viral--genetics<br/>Drug Therapy, Combination<br/>Female<br/>Hepacivirus--genetics<br/>Hepatitis C, Chronic--drug therapy<br/>Heterocyclic Compounds, 4 or More Rings--therapeutic use<br/>Humans<br/>Male<br/>Middle Aged<br/>Ribavirin--therapeutic use<br/>Sofosbuvir--therapeutic use